Trial name | First author | Accrual period | N | Follow-up (months) | Docetaxel arm | Vinorelbine arm |
---|---|---|---|---|---|---|
Tax 326 | Fossella | 1998–2000 | 1218 | 21 | D 75, C 75 q3 wks×6 or D 75, Cb AUC 6 q3 wks×6 | V 25, C 100 q4 wks×6 |
HORG | Georgoulias | 1999–2002 | 413 | 20 | D 100, G 1000 q3 wks×6* | V 30, C 80 q3 wks×6* |
French | Pujol | 1999–2001 | 311 | 25 | D 85, G 1000 q3 wks×8 | V 30, C 100 q4 wks×6 |
Taxobel 303 | Douillard | 1998–2000 | 233 | 43 | D 75 ,C 100 q3 wks×6 | V 30, C 100 q3 wks×6 |
WJTOG 9904 | Kudoh | 2000–2003 | 180 | 26 | D 60 q3 wks×4 | V 25 q4 wks×3 |
*Three additional cycles were given to patients in complete or partial response after the sixth cycle.
Drug doses are indicated in mg/m2 except for carboplatin, which was dosed to obtain an AUC of 6 mg/ml.
AUC, area under the curve; Cb, carboplatin; C, cisplatin; D, docetaxel; G, gemcitabine; HORG, Hellenic Oncology Research Group; N: number of patients randomised; q3/4 wks = every 3/4 weeks; V, vinorelbine; WJTOG, West Japan Thoracic Oncology Group.